

March 30, 2022

Sumitomo Dainippon Pharma Co., Ltd.

Notice of Establishment of Holding Company in China

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura; Securities Code: 4506, First Section of TSE) today announced that its Board of Directors resolved at a meeting held on February 28, 2022, to establish a holding company in China as a wholly owned subsidiary.

1. Objective of the establishment

The Company decided to establish a holding company, “Sumitomo Pharma (China) Co., Ltd.” in China as a wholly owned subsidiary to manage and enhance our China business.

2. Outline of the subsidiary

- (1) Company name: Sumitomo Pharma (China) Co., Ltd.
- (2) Location: 7th Floor, Tower A, China Overseas International Center, Lane 838, South Huangpi Road, Huangpu District, Shanghai
- (3) Representative: Yoshitaka Koketsu (Chairman of the Board)
- (4) Function: Manage the Company’s China business as a holding company
 - General management
 - Shared service
 - Cash pool
- (5) Share capital: 30M US dollars
- (6) Establishment: May 2022 (TBD)
- (7) Ownership: 100% owned by the Company
- (8) Fiscal year-end: December 31
- (9) Number of employees: 15(TBD)

3. Future outlook

The impact of the establishment of the holding company on the Company’s consolidated financial results is minimal.

Contact:

Corporate Communications

Sumitomo Dainippon Pharma Co., Ltd.

TEL: +81-6-6203-1407 (Osaka); +81-3-5159-3300 (Tokyo)